Genetic Technologies Limited (NASDAQ:GENE) Short Interest Update

Genetic Technologies Limited (NASDAQ:GENE) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 25,900 shares, a growth of 48.0% from the October 15th total of 17,500 shares. Based on an average trading volume of 15,700 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genetic Technologies stock. BNP Paribas Financial Markets acquired a new stake in Genetic Technologies Limited (NASDAQ:GENE) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 9,100 shares of the biotechnology company’s stock, valued at approximately $26,000. BNP Paribas Financial Markets owned about 0.24% of Genetic Technologies as of its most recent SEC filing. 0.63% of the stock is owned by institutional investors.

Genetic Technologies Price Performance

NASDAQ:GENE remained flat at $0.77 during mid-day trading on Friday. Genetic Technologies has a 1 year low of $0.67 and a 1 year high of $3.77. The stock has a fifty day simple moving average of $0.77 and a 200 day simple moving average of $1.20. The company has a current ratio of 0.88, a quick ratio of 0.83 and a debt-to-equity ratio of 0.01.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments.